This video is for instructional purposes only. The vaccine vials shown in this video may differ in appearance from actual vials of PNEUMOVAX 23.

PNEUMOVAX 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.

Select Safety Information
PNEUMOVAX 23 is contraindicated in individuals who are hypersensitive to any component of the vaccine.

PNEUMOVAX 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.

The most common adverse experiences reported with PNEUMOVAX 23 in clinical trials were: local reaction at injection site including soreness, erythema, warmth, swelling and induration; and fever <102°F.

In post-marketing experience, injection site cellulitis-like reactions were reported rarely; between 1989 and 2002, when approximately 43 million doses were distributed, the annual reporting rate was <2/100,000 doses. These cellulitis-like reactions occurred with initial and repeat vaccination at a median onset time of 2 days after vaccine administration. Systemic signs and symptoms including fever, leukocytosis and an increase in the laboratory value for serum C-reactive protein may be associated with local reactions.

PNEUMOVAX 23 is not indicated in children less than 2 years of age. Safety and effectiveness in children below the age of 2 years have not been established. Children in this age group respond poorly to the capsular types contained in this vaccine.

Vaccination with PNEUMOVAX 23 may not offer 100% protection from pneumococcal infection.

Before administering PNEUMOVAX 23, please read the Prescribing Information.

PNEUMOVAX 23 is a registered trademark of Merck & Co., Inc.